Capricor shares fell 77% after the FDA rejected its Duchenne muscular dystrophy treatment, deramiocel. The agency cited serious data integrity problems and protocol violations during clinical trials. CEO Linda Marban said, "The FDA has failed the Duchenne community." This decision now clouds the company’s future and its lead experimental asset.

The company was seeking approval for the therapy, known as deramiocel, to preserve upper-limb function in Duchenne muscular dystrophy patients.

Sign up here.

Capricor, whose shares fell 77% in extended trading, ​criticized the decision, with CEO Linda Marban saying "The FDA has failed the Duchenne ​community" and calling the rejection "indefensible."

The agency said there were serious data integrity ⁠problems in a key clinical trial, including unauthorized changes to the analysis plan after ​it began, violations of rules meant to keep patients and researchers from knowing who got ​the treatment, and other protocol violations.

The FDA said the violations "compromise the reliability of the study data." It added that the data is "not considered reliable or interpretable" as proof that the treatment works. It ​also said the treatment did not meet the study's main goals.

CEO Marban said Capricor ​stood firmly behind its data, which she said had been independently validated before the July advisory committee ‌meeting. "It ⁠is irresponsible of the FDA to ignore this, and Duchenne families will pay the price," she said in a statement to Reuters.

Duchenne is a fatal genetic disease that primarily affects boys and causes progressive muscle weakness, loss of mobility, heart complications and premature death.

The ​regulatory rejection deals a ​heavy blow to ⁠Capricor, threatening its lead experimental asset and clouding the company's commercial prospects after months of efforts to salvage the application by narrowing ​its focus to arm and hand movement.

The decision follows a 9-3 vote ​in July ⁠in which the FDA's advisers said the evidence presented at the time did not establish deramiocel's effectiveness in Duchenne-related heart disease.

In August, Capricor had submitted an amended application with 24-month data ⁠from its ​late-stage study, along with extra analyses, focusing specifically on ​upper-limb muscle function.

Reporting by Kunal Das, Siddhi Mahatole, Sahil Pandey and Kamal Choudhury in Bengaluru; Additional reporting by ​Natalia Bueno Rebolledo in Mexico City; Editing by Alan Barona, Perla Velasco and Muralikumar Anantharaman